CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Five Prime Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Five Prime Therapeutics Inc
111 Oyster Point Boulevard
Phone: (415) 365-5600p:415 365-5600 SOUTH SAN FRANCISCO, CA  94080  United States Ticker: 5P85P8
This company was Merged or Acquired on 4/16/2021.
This company ceased filing statements with the SEC on 4/26/2021.
This is a Subsidiary, click here for the Parent Company
Business Summary
Five Prime Therapeutics, Inc. is a United States-based clinical-stage biotechnology company. The Company is focused on developing immune modulators and precision therapies to improve the lives of patients with solid tumor cancer. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. It has developed novel, breakthrough therapies that have potential to alter the course of disease in cancers with few treatment options. The Company’s advanced product candidates include Bemarituzumab (FPA144), FPT155, FPA157 and BMS-986258.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202012/31/2020YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer ThomasCivik 51 4/13/2020 4/13/2020
Chief Financial Officer, Executive Vice President David V.Smith 60 2/28/2019 11/26/2018
Executive Vice President, Chief Medical Officer Helen L.Collins 57 8/20/2019 3/20/2017
6 additional Officers and Directors records available in full report.

Business Names
Business Name
5P8
FPRX

General Information
Number of Employees: 51 (As of 12/31/2020)
Outstanding Shares: 46,572,029 (As of 3/15/2021)
Shareholders: 24
Stock Exchange: NASD
Federal Tax Id: 260038620
Fax Number: (415) 365-5601


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, January 30, 2025